ChEMBL ligand: CHEMBL129 (3'-azt, Azidothymidine, AZT, BWA509U, BW A509U, BW-A509U, BW-A-509U, COMPOUND S, COMPOUND-S, NSC-602670, Retrovir, Zidovudine, Zidovudinum)
DNA polymerase beta in Human [ChEMBL: CHEMBL2392] [GtoPdb: 3231] [UniProtKB: P06746] There should be some charts here, you may need to enable JavaScript!
Human immunodeficiency virus type 1 protease in Human immunodeficiency virus 1 [ChEMBL: CHEMBL243] [UniProtKB: Q72874] There should be some charts here, you may need to enable JavaScript!
Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 [ChEMBL: CHEMBL247] [UniProtKB: Q72547] There should be some charts here, you may need to enable JavaScript!
Plasmodium falciparum [ChEMBL: CHEMBL364] There should be some charts here, you may need to enable JavaScript!
Thymidine kinase in Ureaplasma parvum serovar 3 (strain ATCC 700970) [ChEMBL: CHEMBL1075130] [UniProtKB: Q9PPP5] There should be some charts here, you may need to enable JavaScript!
Thymidine kinase, cytosolic in Human [ChEMBL: CHEMBL2883] [UniProtKB: P04183] There should be some charts here, you may need to enable JavaScript!
Thymidylate kinase in Mycobacterium tuberculosis [ChEMBL: CHEMBL2361] [UniProtKB: P9WKE1] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
DNA polymerase beta in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2392] [GtoPdb: 3231] [UniProtKB: P06746]
ChEMBL	Inhibition of DNA polymerase beta	B	4.7	pIC50	>20000	nM	IC50	J Nat Prod (1995) 58: 1024-1031 [PMID:7561895]
Human immunodeficiency virus type 1 protease in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL243] [UniProtKB: Q72874]
ChEMBL	Inhibitory effect on HIV-1 RT activity using template primer,poly (rA)-oligo (dT)	B	4.3	pIC50	>50000	nM	IC50	J Med Chem (1995) 38: 2038-2040 [PMID:7540208]
ChEMBL	Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RTS (Y181C)	B	7.64	pIC50	23	nM	IC50	J Med Chem (1993) 36: 1291-1294 [PMID:7683725]
ChEMBL	Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RTS (K103 N)	B	7.8	pIC50	16	nM	IC50	J Med Chem (1993) 36: 1291-1294 [PMID:7683725]
ChEMBL	Inhibitory effect on HIV-1 RT activity using template primer,poly (rA)-oligo (dT)	B	8.22	pIC50	6	nM	IC50	J Med Chem (1995) 38: 2038-2040 [PMID:7540208]
ChEMBL	Inhibitory activity against HIV-1 IIIB in CEM-SS infected cells (Experiment 1)	B	6.9	pEC50	126	nM	EC50	Bioorg Med Chem Lett (1999) 9: 803-806 [PMID:10206539]
Human immunodeficiency virus type 1 reverse transcriptase in Human immunodeficiency virus 1 (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL247] [UniProtKB: Q72547]
ChEMBL	Binding affinity to HIV1 reverse transcriptase assessed as compound incorporation into DNA by primer extension assay	B	8.27	pKd	5.4	nM	Kd	J Med Chem (2013) 56: 8765-8780 [PMID:24102161]
ChEMBL	Inhibition of HIV-1 reverse transcriptase.	B	4	pIC50	>100000	nM	IC50	Bioorg Med Chem Lett (1996) 6: 2405-2410
ChEMBL	Compound was evaluated for enzymatic inhibitory activity against recombinant HIV reverse transcriptase	B	4	pIC50	>100000	nM	IC50	Bioorg Med Chem Lett (1998) 8: 1461-1466 [PMID:9873370]
ChEMBL	Inhibition of recombinant reverse transcriptase (RT) in cell-free Quan-T-RT assay system	B	4	pIC50	>100000	nM	IC50	Bioorg Med Chem Lett (1999) 9: 3411-3416 [PMID:10617082]
ChEMBL	Inhibition of recombinant HIV-1 reverse transcriptase	B	4	pIC50	>100000	nM	IC50	Bioorg Med Chem Lett (2000) 10: 87-90 [PMID:10636251]
ChEMBL	Inhibition of HIV-1 reverse transcriptase	B	4	pIC50	>100000	nM	IC50	Bioorg Med Chem Lett (1996) 6: 2411-2416
ChEMBL	Inhibition of HIV1 reverse transcriptase activity after 1 hr by ELISA	B	4.67	pIC50	21430	nM	IC50	Bioorg Med Chem Lett (2011) 21: 574-576 [PMID:21095125]
ChEMBL	Inhibition of HIV1 reverse transcriptase incubated for 1 hr by colorimetric assay	B	4.69	pIC50	20520	nM	IC50	Bioorg Med Chem Lett (2012) 22: 7041-7044 [PMID:23067552]
ChEMBL	Inhibition of HIV1 reverse transcriptase using DIG-labeled dNTPs as substrate after 1 hr by ELISA	B	4.7	pIC50	20140	nM	IC50	Bioorg Med Chem Lett (2016) 26: 1738-1741 [PMID:26944616]
ChEMBL	Inhibition of HIV-1 reverse transcriptase after 1 hr by ELISA plate reader analysis	B	4.74	pIC50	18220	nM	IC50	Bioorg Med Chem Lett (2014) 24: 3426-3429 [PMID:24953602]
ChEMBL	Inhibition of HIV1 reverse transcriptase	B	5.34	pIC50	4540	nM	IC50	Bioorg Med Chem (2013) 21: 1964-1971 [PMID:23415084]
ChEMBL	Inhibition of HIV1 reverse transcriptase M184V mutant-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	B	5.44	pIC50	3600	nM	IC50	J Med Chem (2009) 52: 5356-5364 [PMID:19678643]
ChEMBL	Inhibition of HIV1 wild type reverse transcriptase-mediated viral DNA synthesis in human HOS cells assessed as luciferase activity treated 3 hrs before infection measured after 48 hrs by luminescence assay	B	5.85	pIC50	1400	nM	IC50	J Med Chem (2009) 52: 5356-5364 [PMID:19678643]
ChEMBL	Inhibition of HIV-1 reverse transcriptase from peripheral blood mononuclear cells	B	7	pIC50	<100	nM	IC50	J Med Chem (1991) 34: 3305-3309 [PMID:1720175]
ChEMBL	Inhibition of HIV1 reverse transcriptase p66/p51	B	7.3	pIC50	50	nM	IC50	J Nat Prod (1995) 58: 1024-1031 [PMID:7561895]
ChEMBL	Inhibition of HIV1 reverse transcriptase	B	7.3	pIC50	50	nM	IC50	Bioorg Med Chem (2007) 15: 5519-5528 [PMID:17562366]
ChEMBL	Inhibition of wild type HIV 3B reverse transcriptase in MT2 cells	B	7.3	pIC50	50	nM	IC50	Bioorg Med Chem Lett (2008) 18: 1120-1123 [PMID:18164198]
ChEMBL	Inhibition on HIV1 reverse transcriptase p66/p51	B	7.3	pIC50	50	nM	IC50	Bioorg Med Chem (2009) 17: 1739-1746 [PMID:19179082]
ChEMBL	Concentration required to inhibit HIV reverse transcriptase	B	7.4	pIC50	40	nM	IC50	J Med Chem (1992) 35: 3369-3372 [PMID:1527788]
ChEMBL	Ability to inhibit the HIV-1 reverse transcriptase in cord blood mononuclear cells.	B	7.52	pIC50	30	nM	IC50	J Med Chem (1995) 38: 1-4 [PMID:7837220]
ChEMBL	Inhibitory concentration against human immunodeficiency virus type 1 (HIV-1 strain IIIB RT) reverse transcriptase was determined by triplicate assay at high (~1 pfu/cell) multiplicity of injection (moi)	B	7.77	pIC50	17	nM	IC50	J Med Chem (1998) 41: 10-23 [PMID:9438017]
ChEMBL	antiviral activity in Human immunodeficiency virus-1 as reverse transcriptase activity in culture supernatant	B	7.96	pIC50	11	nM	IC50	J Med Chem (1995) 38: 4106-4114 [PMID:7562946]
ChEMBL	Tested for the inhibition towards HIV-reverse transcriptase	B	8	pIC50	10	nM	IC50	Bioorg Med Chem Lett (1995) 5: 1819-1824
ChEMBL	In vitro inhibitory activity against human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT)	B	8.22	pIC50	6	nM	IC50	J Med Chem (1991) 34: 2231-2241 [PMID:1712395]
ChEMBL	Antiviral activity against Human Immunodeficiency Virus by Reverse transcriptase assay in CEM-SS cells	B	8.51	pIC50	3.1	nM	IC50	J Med Chem (1998) 41: 1252-1262 [PMID:9548815]
ChEMBL	Inhibitory concentration against human immunodeficiency virus type 1 (HIV-1 strain IIIB RT) reverse transcriptase was determined by triplicate assay at low (~0.1 pfu/cell) multiplicity of injection (moi)	B	8.52	pIC50	3	nM	IC50	J Med Chem (1998) 41: 10-23 [PMID:9438017]
ChEMBL	Tested in vitro against HIV-1 MDR using MAGI assay	F	4.6	pEC50	24900	nM	EC50	J Med Chem (2000) 43: 4516-4525 [PMID:11087576]
ChEMBL	Tested in vitro against HIV-1 LAI from MT-4 cells using MTT assay	F	7.42	pEC50	38	nM	EC50	J Med Chem (2000) 43: 4516-4525 [PMID:11087576]
ChEMBL	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay	B	7.77	pEC50	17	nM	EC50	ACS Med Chem Lett (2018) 9: 370-375 [PMID:29670703]
ChEMBL	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	B	7.95	pEC50	11.1	nM	EC50	J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL	Effective concentration that reduces HIV-induced cytopathic effect by 50% was determined by reverse transcriptase (RT) assay.	B	8	pEC50	10	nM	EC50	J Med Chem (1993) 36: 826-830 [PMID:8385224]
ChEMBL	Inhibition of HIV1 RES056 reverse transcriptase K103N/Y181C double mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	B	8.05	pEC50	8.9	nM	EC50	Bioorg Med Chem (2017) 25: 2491-2497 [PMID:28314514]
ChEMBL	Antiviral activity against HIV1 IRLL98 in MT4 cells by MTT assay	F	8.1	pEC50	8	nM	EC50	Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553]
ChEMBL	Inhibition of HIV1 3B reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	B	8.14	pEC50	7.3	nM	EC50	J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL	Inhibition of wild-type HIV1 3B reverse transcriptase infected in human MT4 cells assessed as protection against virus-induced cytotoxicity by MTT assay	B	8.15	pEC50	7	nM	EC50	ACS Med Chem Lett (2018) 9: 370-375 [PMID:29670703]
ChEMBL	Inhibition of HIV1 3B reverse transcriptase Y181C mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	B	8.18	pEC50	6.68	nM	EC50	J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL	Inhibition of HIV-1 reverse transcriptase E138K mutant infected in human MT4 cells assessed as protection against virus-induced cytopathic effect measured at 5 days post infection by MTT assay	B	8.18	pEC50	6.6	nM	EC50	Bioorg Med Chem (2017) 25: 2491-2497 [PMID:28314514]
ChEMBL	Inhibition of HIV1 3B reverse transcriptase Y188L mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	B	8.2	pEC50	6.34	nM	EC50	J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL	Inhibition of HIV1 3B reverse transcriptase K103N mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	B	8.28	pEC50	5.24	nM	EC50	J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL	Inhibition of HIV1 3B reverse transcriptase F227L/V106A double mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	B	8.32	pEC50	4.79	nM	EC50	J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL	Inhibition of HIV1 3B reverse transcriptase L100I mutant infected in human MT4 cells assessed as protection against virus induced cytotoxicity after 5 days by MTT assay	B	8.43	pEC50	3.75	nM	EC50	J Med Chem (2017) 60: 4424-4443 [PMID:28481112]
ChEMBL	Effective concentration in vitro against HIV-1-infected CEM cells relative to uninfected untreated controls	F	8.52	pEC50	3	nM	EC50	J Med Chem (1994) 37: 4297-4306 [PMID:7996541]
ChEMBL	Reverse transcriptase activity was measured in the culture supernatant, concentration that reduces by 50% the HIV produced in the supernatant.	B	8.52	pEC50	3	nM	EC50	J Med Chem (1997) 40: 1550-1558 [PMID:9154976]
ChEMBL	Inhibition of reverse transcriptase of HIV-1 (strain RF)-infected MT-4 cells in RPMI 1640 growth medium in MTM assay	B	8.52	pEC50	3	nM	EC50	J Med Chem (1993) 36: 3784-3794 [PMID:7504733]
ChEMBL	Antiviral activity against HIV1 Y188L mutant in MT4 cells by MTT assay	F	8.52	pEC50	3	nM	EC50	Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553]
ChEMBL	Antiviral activity against HIV1 K103N mutant in MT4 cells by MTT assay	F	8.52	pEC50	3	nM	EC50	Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553]
ChEMBL	Antiviral activity against wild type HIV1 NL4-3 in MT4 cells by MTT assay	F	8.52	pEC50	3	nM	EC50	Bioorg Med Chem Lett (2006) 16: 3541-3544 [PMID:16621553]
ChEMBL	Effective concentration required to inhibit HIV-1 induced cytopathicity by 50% in CEM cells	F	8.52	pEC50	3	nM	EC50	Bioorg Med Chem Lett (2001) 11: 3085-3088 [PMID:11714616]
ChEMBL	Effective concentration required to achieve 50% inhibition of HIV-1 LAI replication in human T4 lymphoblastoid CEM-SS cells.	F	8.7	pEC50	2	nM	EC50	J Med Chem (2000) 43: 1927-1939 [PMID:10821705]
Plasmodium falciparum (target type: ORGANISM) [ChEMBL: CHEMBL364]
ChEMBL	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 after 48 hrs	F	4.7	pIC50	>20000	nM	IC50	Bioorg Med Chem (2010) 18: 8243-8256 [PMID:21044845]
ChEMBL	Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 after 48 hrs	F	4.7	pIC50	>20000	nM	IC50	Bioorg Med Chem (2010) 18: 8243-8256 [PMID:21044845]
ChEMBL	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 48 hrs by FACS analysis in presence of 10 % human serum	F	4.7	pIC50	>20000	nM	IC50	Bioorg Med Chem (2010) 18: 8243-8256 [PMID:21044845]
ChEMBL	Antimalarial activity against Plasmodium falciparum 3D7 after 48 hrs by SYBR green assay	F	4	pEC50	>100000	nM	EC50	Bioorg Med Chem (2010) 18: 7302-7309 [PMID:20833052]
Thymidine kinase in Ureaplasma parvum serovar 3 (strain ATCC 700970) (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL1075130] [UniProtKB: Q9PPP5]
ChEMBL	Inhibition of Ureaplasma parvum thymidine kinase by liquid scintillation counting	B	4.9	pIC50	12500	nM	IC50	Bioorg Med Chem (2010) 18: 3261-3269 [PMID:20378362]
Thymidine kinase, cytosolic in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2883] [UniProtKB: P04183]
ChEMBL	Inhibitory affect against rabbit thymus thymidine kinase	B	5.15	pKi	7000	nM	Ki	J Med Chem (1990) 33: 258-263 [PMID:2153206]
ChEMBL	Inhibitory affect against rabbit thymus thymidine kinase and represented as molt/4F kinase.	B	5.54	pKi	2900	nM	Ki	J Med Chem (1990) 33: 258-263 [PMID:2153206]
ChEMBL	Inhibition of human TK1 by liquid scintillation counting	B	5.52	pIC50	3000	nM	IC50	Bioorg Med Chem (2010) 18: 3261-3269 [PMID:20378362]
Thymidylate kinase in Mycobacterium tuberculosis (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL2361] [UniProtKB: P9WKE1]
ChEMBL	Inhibitory activity against thymidine monophosphate kinase (TMPK) in Mycobacterium tuberculosis	B	4.55	pKi	28000	nM	Ki	Bioorg Med Chem Lett (2003) 13: 3045-3048 [PMID:12941330]
ChEMBL	In Vitro inhibition of Thymidine Monophosphatase Kinase of Mycobacterium tuberculosis (TMPKm)	B	4.55	pKi	28000	nM	Ki	J Med Chem (2003) 46: 3811-3821 [PMID:12930144]
ChEMBL	Competitive inhibition of Mycobacterium tuberculosis TMPK by Lineweaver-Burk analysis	B	4.55	pKi	28000	nM	Ki	Bioorg Med Chem (2011) 19: 7603-7611 [PMID:22061826]

ChEMBL data shown on this page come from version 32:

Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, Magariños MP, Mosquera JF, Mutowo P, Nowotka M, Gordillo-Marañón M, Hunter F, Junco L, Mugumbate G, Rodriguez-Lopez M, Atkinson F, Bosc N, Radoux CJ, Segura-Cabrera A, Hersey A, Leach AR. (2019) 'ChEMBL: towards direct deposition of bioassay data' Nucleic Acids Res., 47(D1). DOI: 10.1093/nar/gky1075. [EPMCID:30398643]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]